Federated Hermes’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $182K | Sell |
53,000
-894,751
| -94% | -$3.07M | ﹤0.01% | 1510 |
|
|
2025
Q1 | $2.11M | Buy |
947,751
+31,514
| +3% | +$70.3K | ﹤0.01% | 919 |
|
|
2024
Q4 | $2.68M | Sell |
916,237
-1,366,459
| -60% | -$4M | 0.01% | 866 |
|
|
2024
Q3 | $5.94M | Sell |
2,282,696
-443,320
| -16% | -$1.15M | 0.01% | 685 |
|
|
2024
Q2 | $8.07M | Sell |
2,726,016
-89,443
| -3% | -$265K | 0.02% | 599 |
|
|
2024
Q1 | $12.8M | Sell |
2,815,459
-302,221
| -10% | -$1.37M | 0.03% | 521 |
|
|
2023
Q4 | $17.8M | Sell |
3,117,680
-136,673
| -4% | -$780K | 0.04% | 417 |
|
|
2023
Q3 | $15M | Sell |
3,254,353
-119,702
| -4% | -$551K | 0.04% | 437 |
|
|
2023
Q2 | $21.8M | Buy |
3,374,055
+469,796
| +16% | +$3.03M | 0.05% | 359 |
|
|
2023
Q1 | $21.9M | Buy |
2,904,259
+381,937
| +15% | +$2.88M | 0.06% | 368 |
|
|
2022
Q4 | $25.6M | Buy |
2,522,322
+418,281
| +20% | +$4.24M | 0.07% | 326 |
|
|
2022
Q3 | $20.8M | Buy |
2,104,041
+367,822
| +21% | +$3.64M | 0.06% | 372 |
|
|
2022
Q2 | $18.5M | Buy |
1,736,219
+448,219
| +35% | +$4.77M | 0.05% | 405 |
|
|
2022
Q1 | $12.6M | Buy |
1,288,000
+460,153
| +56% | +$4.49M | 0.03% | 547 |
|
|
2021
Q4 | $11.8M | Buy |
827,847
+237,847
| +40% | +$3.4M | 0.02% | 602 |
|
|
2021
Q3 | $11.8M | Buy |
590,000
+194,000
| +49% | +$3.89M | 0.02% | 604 |
|
|
2021
Q2 | $8.71M | Buy |
396,000
+346,000
| +692% | +$7.61M | 0.02% | 703 |
|
|
2021
Q1 | $1.7M | Hold |
50,000
| – | – | ﹤0.01% | 1163 |
|
|
2020
Q4 | $2.01M | Buy |
+50,000
| New | +$2.01M | ﹤0.01% | 1061 |
|